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Abstract An immunologic adjuvant is a substance that
enhances the antigen-specific immune response preferably
without triggering one on its own. Silicone, a synthetic
polymer used for reconstructive and cosmetic purposes,
can cause, once injected, local and/or systemic reactions
and trigger manifestations of autoimmunity, occasionally
leading to an overt autoimmune disease. Siliconosis, cal-
cinosis cutis with hypercalcemia and chronic kidney dis-
ease have all been reported in association with silicone
injection. Here, we describe a case of autoimmune/auto-
inflammatory syndrome induced by adjuvants, calcinosis
cutis and chronic kidney disease after liquid silicone mul-
tiple injections in a young man who underwent a sex
reassignment surgery, followed by a review of the litera-
ture. To our knowledge, this is the first report describing
the concomitance of the three clinical conditions in the
same patients. The link between silicone and the immune
system is not completely understood yet and requires fur-
ther reports and investigations with long-term data, in order
to identify the main individual and genetical risk factors
predisposing to the wide spectrum of the adjuvant-induced
responses.
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Introduction
Immune-mediated diseases are caused by a complex of
genetic and environmental factors. A genetically suscepti-
ble subject may develop an autoimmune or inflammatory
disease following the exposure to a specific external factor.
An immunologic adjuvant (word derived from latin adju-
vare, which means help) is a substance that enhances the
antigen-specific immune response, normally without trig-
gering one on its own. Many substances are used in med-
icine as adjuvants, mainly to boost the immune response to
vaccination. These components increase the local reaction
to antigens and subsequently the release of chemokines and
cytokines from T-helper and mast cells. An adjuvant, while
inducing the immune system activation, a desirable effect,
can trigger manifestations of autoimmunity, sometimes
leading to an overt autoimmune disease.
In recent years, four medical conditions, namely sili-
conosis, the Gulf War syndrome (GWS), the macrophagic
myofasciitis syndrome (MMF) and postvaccination phe-
nomena, were linked with previous exposure to an adjuvant
substance. Since these four entities share a similar complex
of symptoms and signs and a common pathogenesis,
Shoenfeld and Agmon-Levin suggested to gather them
together under a common syndrome denominated ‘Au-
toimmune/auto-inflammatory Syndrome Induced by Adju-
vants’ [1] (ASIA), and proposed a set of diagnostic criteria
for this entity (Table 1) [2].
ASIA syndrome can be considered a multifactorial
process triggered by the exposure to certain environmental
factors, such as infections, toxins, drugs, vaccine adjuvants,
biomaterials and stress. Main substances associated with
the onset of ASIA syndrome are squalene (Gulf War syn-
drome), aluminum hydroxide (postvaccination phenomena,
macrophagic myofasciitis syndrome) and silicone
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(siliconosis), while mineral oils, guaiacol and iodine
gadital are less common triggers [3, 4].
Silicone is a synthetic polymer used for reconstructive
and cosmetic purposes. Although it used to be thought of as
an inert material, uncapable to provoke immune activation,
soon after its introduction, it has been associated to the onset
of autoimmune/inflammatory manifestations. In addition,
there are reports in the literature describing the onset of
calcinosis cutis, hypercalcemia and chronic kidney disease in
patients who underwent silicone injections [5]. In this article,
we report a case of siliconosis, calcinosis cutis with hyper-
calcemia and chronic kidney disease after multiple injections
of liquid silicone, followed by a review of the literature.
Materials and methods
We performed a literature search for articles published from
1964 to August 2016. We used the MEDLINE database
(PubMed, National Library of Medicine, Bethesda, MD).
We combined the following main keywords: ASIA syn-
drome, siliconosis, hypercalcemia, chronic kidney disease
and calcinosis cutis. The reference lists of all articles were
scanned for references not identified in the initial research.
Case report
A 48-year-old Hispanic woman presented to our observation
with fever, fatigue, nausea, vomiting, abdominal pain and
diffuse arthralgias. Her clinical history was remarkable for a
male-to-female sex reassignment surgery along with
mastoplasty and multiple injections of liquid silicone,
chronic renal failure, arterial hypertension and dyslipidemia.
She was pretty dehydrated, while the rest of physical
examination was unremarkable except for the presence of
extensive, palpable, non-tender, subcutaneous calcifica-
tions on the lower abdomen and gluteus likely related to the
previous silicone injections. Moreover, she presented
ulcers on both buttocks, in the site of previous silicone
injection, both surrounded by skin hyperpigmentation, the
left one being likely infected.
Laboratory tests showed leukocytosis, increased
inflammatory indices, relevant increase of serum creatinine
(6.4 mg/dl with normal values\1.0 mg/dl), hypercalcemia
(14.7 mg/dl with n.v. \11 mg/dl) and hypercalciuria
(397 mg/24 h), increased alkaline phosphatase (ALP)
(151 UI/L n.n.\50 UI/L), but low serum intact parathy-
roid hormone levels (5.3 pg/ml) and normal 1,25 dihy-
droxyvitamin D levels. HIV serology was negative. Serum
immunoelectrophoresis and Bence Jones protein research
were both negative, thus excluding a multiple myeloma.
Primary hyperparathyroidism was excluded because of low
serum intact parathyroid hormone levels (5.3 pg/ml). Other
possible causes of hypercalcemia such as paraneoplastic
syndrome, milk-alkali syndrome, sarcoidosis or excessive
use of vitamin D were ruled out. Tuberculosis was exclu-
ded as well (quantiferon -TB Gold In-Tube Test nega-
tive). Laboratory workup also included antinuclear
antibodies (ANA), rheumatoid factor (RF), antineutrophil
cytoplasmic antibodies (ANCA) and anti-extractable nu-
clear antigens (ENA) testing that were all negative.
Table 1 Suggested criteria for the diagnosis of ‘ASIA’ (for positive diagnosis of ASIA, fulfillment of either two major or one major and two
minor criteria is required)
Major criteria:
Exposure to an external stimuli (infection, vaccine, silicone, adjuvant) prior to clinical manifestations
The appearance of ‘typical’ clinical manifestations:
Myalgia, Myositis or muscle weakness
Arthralgia and/or arthritis
Chronic fatigue, un-refreshing sleep or sleep disturbances
Neurological manifestations (especially associated with demyelination)
Cognitive impairment, memory loss
Pyrexia, dry mouth
Removal of inciting agent induces improvement
Typical biopsy of involved organs
Minor criteria:
The appearance of autoantibodies or antibodies directed against the suspected adjuvant
Other clinical manifestations (e.g. irritable bowel syndrome)
Specific HLA (i.e. HLA DRB1, HLA DQB1)
Onset of an autoimmune disease (e.g. multiple sclerosis, systemic sclerosis)
ASIA autoimmune/auto-inflammatory syndrome induced by adjuvants
Immunol Res (2016) 64:1142–1149 1143
123
The patient underwent a magnetic resonance imaging
(MRI) of the abdomen which showed numerous subcuta-
neous areas, hyper-intense on T2-weighted sequences,
classifiable as siliconomas (Figs. 1, 2).
A renal biopsy showed severe and diffuse sclerosis,
basal membranes with variable thickness, neutrophil infil-
tration of vessel lumen and hyperplasia of juxtaglomerular
cells. In particular, sclerotic glomerula presented collapsed
basal membranes and deposition of amorphous undercap-
sular collagen. Direct immunofluorescence showed depo-
sition of IgM and C3 in vessel walls and in sclerotic zones.
The ultrastructural examination showed an increase of
mesangial matrix, extended interstitial fibrosis, severe
tubular damage with tubular basal membranes thickened
and rich of granular material.
A diagnosis of ASIA syndrome was made as the patient
fulfilled three of the four major criteria proposed by
Shoenfeld and Agmon-Levin. Prednisone (0.5 mg/Kg)
with massive intravenous hydration and furosemide were
started, with progressive renal function recovery and nor-
malization of calcium levels. A gluteus wound swab
showed the presence of Escherichia coli, so a prompt
antibiotic therapy with ertapenem was administered, with
progressive recovery of the infected lesions. Needless to
say, surgical removal of all scattered lumps was not a
viable option because of the excessive and diffusely infil-
trating presence of silicone all over the body.
Discussion
An immunologic adjuvant is a substance that accelerates
and enhances the antigen-specific immune response.
Adjuvants may act in several ways: by increasing the local
reactions in the site of injection by mimicking danger
signals [6–8]; by inducing a progressive release of the
antigen, hindering its clearance and enabling a longer
exposure of the antigen to antigen-presenting cells; by
promoting the translocation of antigens to the lymph nodes
where antigens can be recognized by T cells; by inducing
the release of inflammatory cytokines [9, 10]; by interact-
ing with toll-like receptors (TLRs) and nucleotide
oligomerization domain (NOD)-like receptors (NLRs) such
as NALP3 inflammasome [11]. The activation of the
immune system triggered by these substances is normally
self-limited. However, in genetically susceptible subjects,
it can be out of control triggering the production of
autoantibodies, and occasionally, an overt autoimmune
disease.
Silicones are a family of synthetic polymers sharing a
silicone-oxygen chain with varying organic side groups.
Since their introduction, they were incorporated into a
myriad of medical products and devices such as breast and
joint implants, ventriculoperitoneal shunts, artificial heart
valves, intraocular lenses and more [12]. The three com-
mon forms of silicone are elastomer (silastic), liquid and
gel. At present, the most commonly used form is gel, which
was first introduced in 1960s for reconstructive and cos-
metic purposes as a component of breast implants (SBI).
Liquid silicone was used for breast augmentation in the
1950 and 1960s until reports of adverse effects appeared in
the United States. Initially thought of as inert material, it
was discovered that liquid silicone can invade deep muscle
tissue and trigger fibrosis, granuloma formation and lym-
phadenopathy. It can migrate through tissue planes to
dependent areas such as the lower abdominal wall, the
inguinal canal and the buttocks [13]. Occasionally, it can
reach the central nervous system through a transfer oper-
ated by macrophages as has been seen for alum [14].
Fibrosis is less effective in barricading a liquid irritant than
a solid one; therefore, these masses are able to grow to
large sizes.
Injection of silicone can trigger both local and systemic
reactions. Following silicone implantation, a capsule forms
around the implant as part of an inflammatory response to a
foreign body [15]. In particular, postoperative wound
Fig. 1 Hyper-intense areas on T2-weighted sequences (indicated by
arrows) represent siliconomas of the buttocks
Fig. 2 Hyper-intense paravertebral siliconomas on T2-weighted
sequences (indicated by arrows)
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healing is characterized by acute inflammation followed by
the formation of a myofibroblast-containing fibrotic cap-
sular tissue with CD4 ? lymphocytes, macrophages and
multinucleated giant cells that surround the implant, known
as ‘Siliconoma’ [16]. The appearance of capsular fibrosis
around the prosthesis is very frequent, but the mechanism
which underlies this phenomenon has not been fully
understood yet. Recently, it has been proposed that silicone
implants trigger a specific antigen-driven local immune
response through activated Th1/Th17 cells, suggesting that
fibrosis is promoted by the production of profibrotic
cytokines as a consequence of faltering function of local T
regulatory cells [17].
Once injected, silicone is able to stimulate the activation
of local macrophages, which results in cytokines and
reactive oxygen species production. The process of oxi-
dation leads to macrophage apoptosis resulting in the
release of silicone containing particles that can be taken up
once again by other macrophages, amplifying the inflam-
matory process [18]. After breast reconstruction with
prostheses containing silicone gel, implant rupture, silicone
leakage through the shell, elastomer fragmentation, cap-
sular fibrosis and capsular contracture, silicone granuloma,
local inflammation and regional lymphadenopathy have
been reported [19, 20]. In addition, patients with immune-
mediated reactions to implanted silicone were found to
have increased IgG in the surrounding tissue and higher
levels of anti-silicone antibodies compared with asymp-
tomatic implanted patients [21]. A remission of such
clinical features following removal of silicone gel breast
implants has been described as well [22, 23]. Another local
side effect to implants can be an allergic reaction to either
silicone or platinum, a catalyst used in silicone polymer-
ization found in minute quantities [24]. Even in the absence
of implant rupture, diffusion of silicone through the
envelope into the surrounding tissues, called ‘bleeding’,
may represent a complication [25]. Bleeding increases with
time and enhances the inflammatory response around the
capsule.
Immune-mediated phenomena and autoimmune diseases
following exposure to silicone have been an issue of debate
for many years. Silicone was previously considered to be
an inert material, but like other adjuvants, it is able to
induce autoimmune-like phenomena termed in the early
1990s ‘Human adjuvant disease’ [26]. The association
between silicone implants and the onset of well-defined
autoimmune diseases have been postulated by several
authors [27], but it still remains controversial. Systemic
adverse reactions to silicone implants have been reported
since 1964 when Miyoshi et al. [28] described the case of
two patients who developed a connective tissue disease
several years following a breast implant augmentation and
coined the acronym of ‘‘human adjuvant disease’’ (HAD).
Thenceforth silicone exposure has been linked to several
autoimmune/rheumatic diseases such as multiple sclerosis
[29] or chronic fatigue syndrome [30]. Case reports and
case series of rheumatoid arthritis, Sjo¨gren’s syndrome,
systemic lupus erythematosus, mixed connective tissue
disease as well as other autoimmune diseases developing in
women who underwent silicone breast implants (SBI)
appeared in the medical literature soon after their intro-
duction, suggesting a causal relationship between breast
implants and the onset of an autoimmune disease [31–33].
Cases of scleroderma following silicone breast implants
have been reported [34]. Lofgren syndrome and neurosar-
coidosis have been described as late complications of
augmentation mammoplasty using silicone gel. Remission
following removal of silicone gel breast implants has been
reported in a patient with debilitating multisystem sar-
coidosis [23, 35]. In a large cohort study published by
Hennekens and colleagues, based on self-reported symp-
toms of 10,830 implanted women, the authors found a
relative risk of 1.25 (95 % CI: 1.08–1.41) for implanted
women compared to non-implanted women for all defined
connective tissue diseases [36]. Nevertheless, a meta-
analysis published by Janowsky et al. [37] that did not
include the former study concluded that there was no
increased risk of defined connective tissue diseases fol-
lowing silicone breast implantation (RR 0.80; 95 % CI:
0.62–1.04). Therefore, since different studies reached
divergent conclusions about the link between silicone
breast implants and defined autoimmune diseases, this
association remains controversial [38, 39].
The finding of different autoantibodies in patients who
underwent silicone breast implants (SBI) [40] is not
uncommon. Zandman-Goddard et al. [41] have shown that
the presence of autoantibodies is increased in symptomatic
silicone breast implants (SBI)-implanted women compared
to asymptomatic women who had undergone the
procedure.
On the other hand, the relationship between silicone
implants and a particular constellation of symptoms, which
did not fulfill the diagnostic criteria for any recognized
connective tissue disease, has been documented in several
studies. Fryzek et al. [42] showed that a group of 1546
patients with silicone breast implants had a statistically
significant increase in 16 of 28 investigated symptoms
when compared to a group of 2496 women who underwent
reduction mammoplasties. These control patients, having
had cosmetic breast surgery, attenuated the possibility of
confounding factors. Many of these symptoms satisfied
several criteria for fibromyalgia and chronic fatigue syn-
drome. Vera-Lastra et al. [43] recently published a case
series of 50 patients with ASIA syndrome after illegal
injection of foreign substances. Among all patients, thirty
(60 %) presented with non-specific manifestations of
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autoimmune rheumatic diseases and twenty (40 %) ful-
filled the criteria for a defined autoimmune disease. All
patients were treated with corticosteroids and had clinical
improvement. A surgical removal of the foreign material
was performed whenever possible, and most patients
showed clinical improvement. Vasey et al. [44] found a
statistically significant correlation between silicone breast
implants and the presentation of many aspecific signs and
symptoms such as body ache, joints pain, myalgia, fatigue,
impaired cognition and others. Cohen Tervaert et al. [18]
published an interesting study in which they evaluated 32
patients who formerly underwent silicone-filled breast
implants surgery, showing symptoms suggestive for
incompatibility with the implants. These patients were
evaluated for ASIA syndrome, immunodeficiency and
autoimmune diseases. Seventeen over 32 patients were
diagnosed with a systemic autoimmune disease, and 15 of
them showed impaired humoral immune system. All
patients suffered from an array of signs and symptoms and
fulfilled the diagnostic criteria for ASIA. Median time
between start of complaints and prosthesis implantation
was 10 years (2–24 years). Patients with enlarged lymph
nodes underwent a biopsy, and the most common histo-
logical finding was a foreign body reaction with granulo-
matous inflammation containing multiple giant cells
suggestive of biopsy-proven siliconosis. Therefore, the
exposure to silicone in genetically prone subjects can
trigger the development of an array of symptoms and signs
such as body ache, abnormal fatigue, impaired cognition,
depression, dry eyes, dry mouth, skin abnormalities,
paresthesia, swollen and tender axillary glands, unex-
plained fever, hair loss, headache and morning stiffness
that can be referred to as ‘siliconosis’. Hence, the link
between silicone and autoimmunity should not be limited
by the constraints of defined diseases, but rather correlate
to the relatively prevalent non-defined symptoms.
In order for silicone to act as an environmental trigger,
there has to be a genetic predisposition for developing such
clinical conditions [45]. The relationship between genetic
susceptibility and environmental factors has gained
increased attention and is discussed extensively in recent
literature, including discussions of geoepidemiology, epi-
genetics, infection, animal models, use of twins and gender
[46]. The case of two HLA-matched sisters who both
received silicone breast implants and developed poly-ar-
ticular arthritis and neurological symptoms has been
described [47]. Although silicone implants are safe for the
vast majority of subjects, screening for autoimmune phe-
nomena and genetic testing can be useful tools for future
risk stratification before implantation to help avoid adverse
events in predisposed subjects [48].
Current generation implants are designed with a thicker
shell, more cohesive gel and a barrier coating on the inner
surface of the outer shell to decrease silicone leakage.
However, Colaris et al. [49] recently published the results
of a study in which they compared the clinical manifesta-
tions of two cohorts (one hundred patients each) with ASIA
syndrome secondary to silicone breast implants, the first
one diagnosed in Mastricht in 2014 and the second in
Baylor College of Medicine (Houston) between 1985 and
1992. The authors did not find substantial differences in
terms of clinical manifestations between the two cohorts;
therefore, they concluded that despite changes in the
principal constituents of the silicone implants during the
past 50 years, silicone remained an adjuvant that may
‘bleed’ and subsequently may be a chronic stimulus to the
immune system resulting in similar clinical manifestations.
Calcinosis cutis is a group of disorders initially descri-
bed by Virchow in 1855, in which calcium is deposited in
the skin. Calcium phosphate deposition occurs in response
to local or systemic factors that drive the concentration
above its solubility product [5]. Dystrophic calcinosis
occurs in a normal metabolic state when tissue has been
damaged or devitalized by some pathologic process. It is
thought that damaged tissue exposes denatured proteins
which bind to free phosphate, and hence, the calcium reacts
with bound phosphate to precipitate calcium phosphate
crystals. These crystals in turn increase the tissue damage,
propagating the process and leading to the formation of
giant accretions. These accretions are often the focus of
intense granulomatous fibrosis which limits their growth
[50]. Calcinosis cutis occurs most often in association with
chronic kidney disease, cancer, [51] and autoimmune
conditions such as CREST syndrome (CC, Raynaud’s
phenomenon, esophageal dysfunction, sclerodactyly and
telangiectasia) [52].
Hypercalcemia in association with granulomatous dis-
eases (especially sarcoidosis) has been extensively descri-
bed in the literature. It has been related to a dysregulated
activity of 1a-hydroxylase enzyme (1aHE) in giant cells
and macrophages from granulomas that leads to an
uncontrolled production of 1,25-dihydroxycholecalciferol
(1,25D3) in calcified granulomas [53]. Macrophage 1a-
hydroxylase enzyme is completely unregulated by feed-
back mechanisms unlike renal 1a-hydroxylase enzyme
[54]. Corticosteroids are valuable in all forms of hyper-
calcemia as they reduce gastrointestinal calcium absorption
and inhibit osteoclast function. But, they are particularly
effective in granulomatous diseases as sarcoidosis because
of their effects on vitamin D metabolism. Even though they
have no effect on 1a-hydroxylase of renal tubular cells,
they are potent inhibitors of macrophage 1a-hydroxylase
enzyme [55]. An alternative explanation for granulomatous
diseases-associated hypercalcemia is the overproduction of
PTH-related proteins (PTHrP). Increased serum levels of
PTHrP have been documented in sarcoidosis along with
1146 Immunol Res (2016) 64:1142–1149
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immunohistochemical staining for PTHrP of macrophages
and multinucleated giant cells within the granulomatous
tissue [56]. Corticosteroids bind to cytokine promoter
regions in the macrophage nucleus down-regulating IL-6
and IFN-gamma expression, and ultimately leading to a
reduced PTHrP production by macrophages [57].
The association between silicone injection, granulomas
and hypercalcemia has been reported since 1984 [58], and
there are several reports in the literature [59–62]. As for the
other granulomatous diseases, hypercalcemia is likely the
consequence of a dysregulated production of 1,25-dihy-
droxivitamin D by activated macrophages (induced by
tumor necrosis factor-a and interferon-c, and inhibited by
corticosteroids) [63] and/or an increase of PTHrP levels
(stimulated by TNF-a and IL-6) [64]. This hypothesis is
supported by the excellent response of hypercalcemia to
glucocorticoid therapy which decreases PTHrP levels and
inhibits the macrophage-derived 1-a-hydroxilase leading to
a 1,25-dihydroxivitamin D reduction. Minocycline,
cyclosporine and allopurinol have been used with some
success as well [65]. Of note, hydroxychloroquine and
ketoconazole have been shown to be effective in treating
hypercalcemia in sarcoidosis [66]. In contrast to long-term
steroids, their milder side effect profiles might make them
preferable candidates, but their exact role in treating sili-
conomas and paraffinomas is still to be explored. Further
studies are necessary to better understand the pathophysi-
ological mechanisms of silicone-induced hypercalcemia
and establish the best treatment options.
Renal failure has been extensively described in granu-
lomatous diseases, such as sarcoidosis. The main patho-
physiological mechanism of kidney damage seems to be a
granulomatous inflammation confined to the tubulointer-
stitial compartment [67], but interstitial and membranous
nephritis without any evidence of granuloma has been
reported as well [68]. Nevertheless, the exact mechanism
of development of renal failure in siliconomas- or paraffi-
nomas-associated granulomatous disease is still unclear
and further reports are needed.
The peculiarity of our case is represented by the com-
plex clinical picture with the coexistence of the three main
clinical manifestations related to silicone injections being
the autoimmune/inflammatory phenomena, calcinosis cutis
with hypercalcemia, and chronic kidney disease. To our
knowledge, this is the first report describing the concomi-
tance of the three conditions in the same patients. As we
observed in our patient, when the surgical removal of sil-
iconomas is not possible, corticosteroids represent an
excellent treatment option with a very good overall clinical
response.
Most of the reports available in the literature suggest
that silicone implants cause a negligible and non-specific
foreign body reaction. Occasionally, they can trigger
autoantibodies production and autoimmune diseases, but
they are more likely associated with an array of non-de-
fined rheumatic symptoms. Nevertheless, as analyzed by
Jara et al. [69] in a recent systematic review regarding
severe manifestations of ASIA syndrome, even though the
percentage of severe cases is small (about 7 % of all cases
of ASIA syndrome), this condition can be life-threatening.
The relationship between silicone and the immune sys-
tem requires further reports and investigations with long-
term data in order to identify the main individual and
genetic risk factors predisposing to the wide spectrum of
the adjuvant-induced responses.
Conclusion
Silicone injections can be very harmful, triggering in the
same patient the onset of ASIA syndrome, calcinosis cutis,
hypercalcemia, and chronic kidney disease. In the event of
such life-threatening manifestations, surgical removal of
prostheses should be mandatory. When eliminating the
trigger is not possible, as in our patient, corticosteroids are
the best and most effective therapy.
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